Fall Allergies: The Pharmacist’s Role in Allergic Rhinitis Symptom Management and Patient Counseling

Thom Kim Nguyen, PharmD, BCPS, CTTS
Published Online: Monday, August 11, 2014
Supported by educational grants from Meda Pharmaceuticals, Inc, and Merck Sharp & Dohme Corp.

Fall Allergies: The Pharmacist’s Role in Allergic Rhinitis Symptom Management and Patient Counseling

Thom Kim Nguyen, PharmD, BCPS, CTTS
Clinical Assistant Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Clinical Coordinator, Ambulatory Care
Hunterdon Medical Center
Flemington, New Jersey

Activity Overview
This activity is intended to provide education to community pharmacists on how to identify triggers of allergic rhinitis, as well as manage and counsel patients who suffer from it during the fall.

After participating in this activity, participants should be able to:
  • Identify potential triggers of allergic rhinitis (AR) in the fall
  • Select management strategies for fall AR, including OTC and prescription pharmacotherapy, immunotherapy, allergen avoidance, and alternative medicine
  • Implement effective counseling techniques to assist with optimal symptom management in patients with AR triggered by fall allergens
Target audience: Pharmacists
Type of activity: Knowledge
Release date: August 8, 2014
Expiration date: August 5, 2016
Estimated time to complete activity: 2.0 hours
Fee: Free

Description: Pharmacy Times/Ascend Media Office of Continuing Professional EducationPharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-14-063-H01-P. The activity is available for CE credit through August 5, 2016.

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues